Reclassification request for ulipristal acetate EC pills raises concerns in Italy
July 2025. In February 2025, a scientific society in Italy submitted a formal request to reclassify emergency contraceptive pills with ulipristal acetate (UPA). The request cited findings from a proof-of-concept study that explored the potential use of UPA for medical abortion.
Since becoming available without prescription in 2015, UPA emergency contraception has played a significant role in preventing unintended pregnancies in Italy, according to the Ministry of Health.
The reclassification request has prompted concern among some reproductive health advocates and medical professionals, as reflected in the editorial published in the European Journal of Contraception and Reproductive Health Care.
Ulipristal acetate (UPA) is the active ingredient in the newer formulation of EC pills, available in Europe since 2009. Like many medications, UPA is being studied for other medical uses, including fibroids, breast cancer, and abnormal uterine bleeding treatment and/or prevention. Research into alternative indications is common and does not necessarily change the established safety and efficacy profile of a drug in its approved use. Learn more about it here and in the brief “Uses of ulipristal acetate beyond emergency contraception“.
